This bottleneck in research funding threatens research that took decades to build, as well as the cures of tomorrow. Publicly-funded research is the highest economic yield there is, with 2.5X of economic gains for every $.
Call your Senator and Rep to ask them to protect federal research!
The New England Journal of Medicine Blinatumomab in Standard-Risk B-Cell ALL in Children A Research Summary based on Gupta S et al. | 10.1056/NEJMoa2411680 | Published on December 7, 2024 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
The addition of blinatumomab after induction chemotherapy in children with standard-risk disease of average or higher risk of relapse significantly improved disease-free survival. Full AALL1731 phase 3 trial results: nej.md/49CVkc1
#MedSky #PedSky #Hematology
Thrilled to author this article with two renowned pediatrician scientists, vaccinologists and friends, Drs. Stanley Plotkin and Mark Schleiss, as we await results of the 1st phase 3 trial of a #CMV vaccine!
JCI - A vaccine against cytomegalovirus: how close are we? www.jci.org/articles/vie...